Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury
Preclinical study published in Brain Research (2026)
Abstract
BACKGROUND: Ischemic stroke (IS) is a leading cause of death and disability worldwide. Hypercoagulability and thrombus formation play critical roles in its pathogenesis. Leech-derived peptides, especially those obtained from Whitmania pigra, have demonstrated potential antithrombotic and neuroprotective effects. This study aimed to investigate the therapeutic efficacy and underlying mechanisms of a leech peptide in a rat model of cerebral ischemia/reperfusion injury. METHODS: Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion followed by reperfusion to establish the IS model. Rats received low-dose or high-dose leech peptide, edaravone as a positive control, or saline. Behavioral assessments, infarct volume measurement, laser speckle imaging for cerebral perfusion, and histopathology were performed. Hemorheology and coagulation parameters were analyzed. Additionally, thrombin levels and fibrinolytic factors were evaluated using ELISA. Biosafety was assessed through hemolysis and histological evaluation of major organs. RESULTS: Leech peptide significantly reduced infarct volume, improved neurological scores, enhanced cerebral perfusion, and preserved brain tissue structure. It modulated thrombin-related parameters, ameliorated coagulation dysfunction, and modulated fibrinolysis-associated factors, thereby contributing to the restoration of coagulation-fibrinolysis homeostasis. Low-dose treatment showed comparable or superior efficacy to the high dose with better safety. No significant toxicity or hemolysis was observed. CONCLUSIONS: Leech peptide derived from Whitmania pigra exerts neuroprotective effects in cerebral ischemia/reperfusion injury through anticoagulation and thrombolysis. These findings support its potential as a novel candidate for IS therapy. TRIAL REGISTRATION: Not applicable. This study did not involve human participants.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Anticoagulant peptide LR from Whitmania pigra reduces infarct volume and improves neurological scores in murine cerebral ischemia-reperfusion model via thrombin inhibition.
Por qué esto importa para la hirudoterapia
Este estudio investigó la eficacia terapéutica de un péptido derivado de la sanguijuela Whitmania pigra en un modelo de rata de lesión por isquemia/reperfusión cerebral (oclusión de la arteria cerebral media), evaluando puntuaciones neurológicas, volumen del infarto, perfusión cerebral mediante imagen de moteado láser, hemorreología, parámetros de coagulación, niveles de trombina y factores fibrinolíticos. El péptido de sanguijuela redujo significativamente el volumen del infarto, mejoró las puntuaciones neurológicas y la perfusión cerebral, moduló los parámetros relacionados con la trombina y la fibrinólisis, y restauró la homeostasis coagulación-fibrinólisis, mostrando la dosis baja una eficacia comparable o superior y sin toxicidad ni hemólisis significativas. Estos hallazgos son relevantes para la hirudoterapia, ya que demuestran efectos neuroprotectores y antitrombóticos de un péptido específico de sanguijuela en un modelo de ictus. Sin embargo, este estudio se realizó exclusivamente en ratas; no se presentan datos en humanos, y la traslación clínica requeriría validación adicional.
Citación
Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury.
Liu R et al. · Brain research, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026